Accurate diagnosis and evaluation of HCC is important for improving the efficiency of HCC treatment and patient prognosis. Glypican-3 (GPC3) has been considered as a promising diagnostic and prognostic biomarker and a target for immune-therapeutic in HCC. Our study aimed to investigate the utility of IDEAL IQ MRI to prospectively evaluate the expression status of GPC3. Our results showed that the intratumoral R2* value was significantly higher in the positive-GPC3 HCC patients than in the negative-GPC3 HCC patients (P=0.003). The IDEAL IQ MRI may have potential for non-invasively predict GPC3 expression status.